Thursday, July 16, 2015
Grand Hall and Gallery, Ground Floor & 1st Floor (Maritim Hotel)
Emma Lorenzen, Ph.D. student, DVM
,
Chlamydia Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
Frank Follmann
,
Chlamydia Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
Sarah Bøje
,
Veterinary Reproduction and Obstetrics, Department of Large Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Karin Erneholm
,
Veterinary Reproduction and Obstetrics, Department of Large Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Anja Olsen
,
Chlamydia Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
Jørgen Agerholm
,
Veterinary Reproduction and Obstetrics, Department of Large Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Gregers Jungersen
,
Section for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, Copenhagen, Denmark
Peter Andersen
,
Chlamydia Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark
A vaccine is needed to combat the continued worldwide spread of genital Chlamydia and it is crucial for the vaccine to elicit a mucosal immune response to be protective. Until now, it has not been possible to establish a significant mucosal immune response with traditional vaccination strategies. We have used an advanced minipig model of human genital Chlamydia to evaluate a combined immunization strategy, with an intramuscular (IM) immunization and an intranasal (IN) booster immunization. The vaccine was formulated with CAF01 adjuvant, known to induce a strong Th1/Th17 response.
We found that IM priming immunization with CAF01 adjuvant raised a significant systemic and genital IgG response, and a significant cell-mediated IFN-ɣ and IL-17A response from re-stimulated PBMCs and lymph node cells. Mucosal (IN) boosting induced significant levels of IgA in the nasal cavity and following vaginal infection a significant secretory IgA response on the genital surface, which correlated with significant lower bacterial shedding.
This study reveals that by combining IM and IN immunization, it is possible to establish a significant systemic and mucosal immune response in the advanced minipig model of human genital Chlamydia. It paves the way for the future Chlamydia vaccine development and induction of genital immunity in general.
